ArticlePloS one2025
Low-dose radiation ameliorates doxorubicin-induced renal injury via reducing oxidative stress and protecting mitochondrial function.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Inhibition of Mitochondrial Fission by Mdivi-1 Alleviates Doxorubicin-Induced Nephrotoxicity in a Rat Model of D-Galactose-Induced Accelerated Renal Aging.Biomolecules · 2026Article
- Dichloroacetate nanoparticles and doxorubicin combinatorial treatment augment the hepato-renal function in Ehrlich ascites carcinoma cells.BMC research notes · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Doxorubicin (DOX) is a well-established chemotherapy drug, but its clinical application is restricted due to significant tissue toxicity, of which nephrotoxicity is a serious adverse reaction. Low-dose radiation (LDR) exerts effects through stimulating diverse cell and molecular mechanisms, which has been shown to have anti-inflammatory and alter immune adaptation effects. This study aims to investigate how LDR protects against DOX-induced nephrotoxicity and to explore the underlying mechanism involved. Sixty mice were randomly divided into control (CTR), LDR, DOX, and combination (COM) group. Nephrotoxicity was induced by injecting a single dose of DOX (7.5 mg/kg) in mice abdominal cavity, and LDR was performed 72 h before DOX treatment. Histological analysis, immunohistochemical analysis, immunofluorescence analysis and western-blotting were used to detect the related indicators. Research data was showed as mean ±SD and tested by One-way ANOVA. The results showed that compared with DOX group, the contents of serum UREA, UA, and the expression level of Bax and caspase 9 were significantly reduced in COM group (P<0.05). Western-blotting and immunohistochemical analysis showed that the expression level of MDA and Nrf2 in COM group were significantly lower than that in DOX group (P<0.05). In addition, the activity of complex Ⅰ, ATP, NDUFA1 and CYC1 were enhanced in COM group compared with DOX group (P<0.05). All the results suggested that LDR pretreatment prevented excessive accumulation of peroxides, restored antioxidants activity (SOD, GSH, CAT), activated Nrf2/HO-1/NQO1 signaling pathway, attenuated damage to the mitochondrial respiratory chain, and protected kidney cells from DOX attack. This study demonstrated that LDR could effectively and safely inhibit the progression of DOX-induced nephrotoxicity. Future studies should further investigate the mechanism of LDR protecting tissues from DOX-induced damage and find an optimal radiation dose for humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.